Advertisement

Hybridoma Technology for the Generation of Monoclonal Antibodies

  • Chonghui ZhangEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 901)

Abstract

Hybridoma technology has long been a remarkable and indispensable platform for generating high-quality monoclonal antibodies (mAbs). Hybridoma-derived mAbs have not only served as powerful tool reagents but also have emerged as the most rapidly expanding class of therapeutic biologics. With the establishment of mAb humanization and with the development of transgenic-humanized mice, hybridoma technology has opened new avenues for effectively generating humanized or fully human mAbs as therapeutics. In this chapter, an overview of hybridoma technology and the laboratory procedures used routinely for hybridoma generation are discussed and detailed in the following sections: cell fusion for hybridoma generation, antibody screening and characterization, hybridoma subcloning and mAb isotyping, as well as production of mAbs from hybridoma cells.

Key words

Cell fusion ELISA Flow cytometry Hybridoma technology Immunohistochemistry Immunization Monoclonal antibody Myeloma cells Therapeutic antibody Screening 

Notes

Acknowledgments

The author gratefully acknowledges Lena Kikuchi and Nancy Chan for their expertise in hybridoma generation and the technical assistance for validating the protocols described here. The author is especially thankful to Dr. Peter LeMotte, Dr. Thomas Pietzonka and Dr. John Hastewell for helpful advice and support, and to Yuxiang Zhang for his assistance in editing the illustrations in this manuscript.

References

  1. 1.
    Köhler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495–497PubMedCrossRefGoogle Scholar
  2. 2.
    Little M, Kipriyanov SM, Gall FL, Moldenhauer G (2000) Of mice and men: hybridoma and recombinant antibodies. Immunol Today 21: 364–370PubMedCrossRefGoogle Scholar
  3. 3.
    An Z (2010) Monoclonal antibodies—a proven and rapidly expanding therapeutic modality for human diseases. Protein Cell 1:319–330PubMedCrossRefGoogle Scholar
  4. 4.
    Weiner LM (2007) Building better magic bullets—improving unconjugated monoclonal antibody therapy for cancer. Nat Rev Cancer 7: 701–706PubMedCrossRefGoogle Scholar
  5. 5.
    Schlossman SF et al (1995) Leucocyte typing V: white cell differentiation antigens. Oxford University Press, OxfordGoogle Scholar
  6. 6.
    Matesanz-Isabel J, Sintes J, Llinàs L et al (2011) New B-cell CD molecules. Immunol Lett 134:104–112PubMedCrossRefGoogle Scholar
  7. 7.
    Kung P, Goldstein G, Reinherz EL, Schlossman SF (1979) Monoclonal antibodies defining distinctive human T cell surface antigens. Science 206:347–349PubMedCrossRefGoogle Scholar
  8. 8.
    Reinherz EL, Kung PC, Goldstein G, Schlossman SF (1979) Separation of functional subsets of human T cells by a monoclonal antibody. Proc Natl Acad Sci U S A 76:4061–4065PubMedCrossRefGoogle Scholar
  9. 9.
    Meuer SC, Hussey RE, Hodgdon JC et al (1982) Surface structures involved in target recognition by human cytotoxic T lymphocytes. Science 218:471–473PubMedCrossRefGoogle Scholar
  10. 10.
    Zhang C, Ao Z, Seth A, Schlossman SF (1996) A mitochondrial membrane protein defined by a novel monoclonal antibody is preferentially detected in apoptotic cells. J Immunol 157: 3980–3987PubMedGoogle Scholar
  11. 11.
    Zhang C (1998) Monoclonal antibody as a probe for characterization and separation of apoptotic cells. In: Zhu L, Chun J (eds) Apoptosis detection and assay methods. BioTechniques series on molecular laboratory methods. BioTechniques Books, Eaton Publishing, Natick, MA, pp 63–73Google Scholar
  12. 12.
    Bok RA, Small EJ (2002) Bloodborne biomolecular markers in prostate cancer development and progression. Nat Rev Cancer 2:918–926PubMedCrossRefGoogle Scholar
  13. 13.
    Wagner PD, Maruvada P, Srivastava S (2004) Molecular diagnostics: a new frontier in cancer prevention. Exp Rev Mol Diagn 4:503–511CrossRefGoogle Scholar
  14. 14.
    Jones PT, Dear PH, Foote J, Neuberger MS, Winter G (1986) Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321:522–525PubMedCrossRefGoogle Scholar
  15. 15.
    Riechmann L, Clark M, Waldmann H, Winter G (1988) Reshaping human antibodies for therapy. Nature 332:323–327PubMedCrossRefGoogle Scholar
  16. 16.
    Smith SL (1996) Ten years of Orthoclone OKT3 (muromonab-CD3): a review. J Transpl Coord 6:109–119PubMedGoogle Scholar
  17. 17.
    Lupo L, Panzera P, Tandoi F et al (2008) Basiliximab versus steroids in double therapy immunosuppression in liver transplantation a prospective randomized clinical trial. Transplantation 86:925–931PubMedCrossRefGoogle Scholar
  18. 18.
    Van den Brande JM, Braat H, van den Brink GR et al (2003) Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s disease. Gastroenterology 124:1774–1785PubMedCrossRefGoogle Scholar
  19. 19.
    Chan AC, Carter PJ (2010) Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 10:301–316PubMedCrossRefGoogle Scholar
  20. 20.
    Maloney DG, Grillo-López AJ, White CA et al (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 90:2188–2195PubMedGoogle Scholar
  21. 21.
    Meissner HC, Welliver RC, Chartrand SA et al (1999) Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion. Pediatr Infect Dis J 18:223–231PubMedCrossRefGoogle Scholar
  22. 22.
    Blattman JN, Greenberg PD (2004) Cancer immunotherapy: a treatment for the masses. Science 305:200–205PubMedCrossRefGoogle Scholar
  23. 23.
    Reichert JM (2011) Antibody-based therapeutics to watch in 2011. mAbs 3:76–99PubMedCrossRefGoogle Scholar
  24. 24.
    McCafferty J, Griffiths AD, Winter G, Chiswell DJ (1990) Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348:552–554PubMedCrossRefGoogle Scholar
  25. 25.
    Hoogenboom HR (2005) Selecting and screening recombinant antibody libraries. Nat Biotechnol 23:1105–1116PubMedCrossRefGoogle Scholar
  26. 26.
    Traggiai E, Becker S, Subbarao K et al (2004) An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 10:871–875PubMedCrossRefGoogle Scholar
  27. 27.
    Lanzavecchia A, Bernasconi N, Traggiai E et al (2006) Understanding and making use of human memory B cells. Immunol Rev 211: 303–309PubMedCrossRefGoogle Scholar
  28. 28.
    Nossal GJV (1992) The molecular and cellular basis of affinity maturation in the antibody response. Cell 68:1–2PubMedCrossRefGoogle Scholar
  29. 29.
    Jakobovits A, Amado RG, Yang X, Roskos L, Schwab G (2007) From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat Biotechnol 25:1134–1143PubMedCrossRefGoogle Scholar
  30. 30.
    Brüggemann M, Neuberger MS (1996) Strategies for expressing human antibody repertoires in transgenic mice. Immunol Today 17: 391–397PubMedCrossRefGoogle Scholar
  31. 31.
    Green LL (1999) Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J Immunol Methods 231:11–23PubMedCrossRefGoogle Scholar
  32. 32.
    Lonberg N (2005) Human antibodies from transgenic animals. Nat Biotechnol 23: 1117–1125PubMedCrossRefGoogle Scholar
  33. 33.
    Davis CG, Gallo ML, Corvalan JRF (1999) Transgenic mice as a source of fully human antibodies for the treatment of cancer. Cancer Metastasis Rev 18:421–425PubMedCrossRefGoogle Scholar
  34. 34.
    Zhang C, Xu Y, Gu J, Schlossman SF (1998) A cell surface receptor defined by a mAb mediates a unique type of cell death similar to oncosis. Proc Natl Acad Sci U S A 95:6290–6295PubMedCrossRefGoogle Scholar
  35. 35.
    Yonehara S, Ishii A, Yonehara M (1989) A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 169:1747–1756PubMedCrossRefGoogle Scholar
  36. 36.
    Trauth BC, Klas C, Peters AMJ et al (1989) Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245:301–305PubMedCrossRefGoogle Scholar
  37. 37.
    Kearney JF, Radbruch A, Liesegang B, Rajewsky K (1979) A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. J Immunol 123:1548–1550PubMedGoogle Scholar
  38. 38.
    Shi S-R, Shi Y, Taylor CR (2011) Antigen retrieval immunohistochemistry: review and future prospects in research and diagnosis over two decades. J Histochem Cytochem 59:13–32PubMedCrossRefGoogle Scholar
  39. 39.
    D’Amico F, Skarmoutsou E, Stivala F (2009) State of the art in antigen retrieval for immunohistochemistry. J Immunol Methods 341:1–18PubMedCrossRefGoogle Scholar
  40. 40.
    Glassy M (1988) Creating hybridomas by electrofusion. Nature 333:579–580PubMedCrossRefGoogle Scholar
  41. 41.
    Ohnishi K, Chiba J, Goto Y, Tokunaga T (1987) Improvement in the basic technology of electrofusion for generation of antibody-producing hybridomas. J Immunol Methods 100:181–189PubMedCrossRefGoogle Scholar
  42. 42.
    Long WL, McGuire W, Palombo A, Emini EA (1986) Enhancing the establishment efficiency of hybridoma cells: use of irradiated human diploid fibroblast feeder layers. J Immunol Methods 86:89–93PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.NIBR Biologics Center, Novartis Institutes for BioMedical ResearchCambridgeSwitzerland

Personalised recommendations